Clinical Effect of Yin Yang Regulating Moxibustion on Diarrhea-predominant Irritable Bowel Syndrome
Article Sidebar
Main Article Content
Abstract
Abstract
Objective: To evaluate the clinical effect of Yin Yang regulating moxibustion on diarrhea-predominant irritable bowel syndrome（IBS-D） and explore its therapeutic mechanism.
Methods: Sixty patients with diarrhea irritable bowel syndrome (December 2022 to December 2023) were divided randomly and averagely into a control group and an observation group using a random number table method. The control group was given a trimebutine maleate capsule, while the observation group was given Yin Yang regulating moxibustion in addition to oral trimebutine maleate capsules. The treatment course was 4 weeks. Observation or detection indicators: Irritable Bowel Syndrome Severity Score (IBS-SSS), gut microbiota structure and diversity, brain gut peptide indicators (5-HT, SP, NPY), safety before and after treatment in both groups of patients.
Results: There was no statistically significant difference in the symptom severity score, gut microbiota structure and diversity, and brain gut peptide levels between the two groups before treatment (p > 0.05). After treatment, the symptom severity scores of both groups of patients were lower than before treatment, and the treatment group had lower scores than the control group, with statistical significance (p < 0.05). After treatment, the Simpson index of the treatment group was lower than before treatment, and the Shannon index was higher than before treatment, with statistical significance (p < 0.05). The Simpson index of the control group was lower than before treatment, and the Shannon index was higher than before treatment, with no statistical significance (p > 0.05). Inter-group comparison showed that the Simpson index of the treatment group was lower than that of the control group, and the Shannon index was higher than that of the control group after treatment, and the differences were statistically significant. After treatment, the serum levels of 5-TH and SP in both groups were lower than before treatment, and the treatment group was lower than the control group, with statistically significant differences (p < 0.05). The serum NPY levels were higher than before treatment, and the treatment group was higher than the control group, with statistically significant differences (p < 0.05). During the treatment process, neither group of patients experienced skin allergies or serious adverse reactions related to the treatment.
Conclusion: Yin-Yang regulating moxibustion is safe and effective in treating diarrhea and irritable bowel syndrome, and is worthy of clinical promotion. Its therapeutic mechanism may be related to its regulation of brain-gut peptide levels and improvement of intestinal microbiota.
Downloads
Article Details
Copyright (c) 2025 Qingqing C, et al.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Hou X, Liu J, Xiong L, Zuo X. Collaborative Group on Functional Gastrointestinal Diseases of the Digestive Disease Branch of the Chinese Medical Association, Gastrointestinal Dynamics Group of the Digestive Disease Branch of the Chinese Medical Association, Consensus opinion of experts on irritable bowel syndrome in China in 2020. Chin J Gastroenterol. 2020;40(12):803-818.
Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016;150(6):1257-1261. Available from: https://doi.org/10.1053/j.gastro.2016.03.035
Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of the Rome Foundation Global Study. Gastroenterology. 2021;160:99–114.e3. Available from: https://doi.org/10.1053/j.gastro.2020.04.014
Singh P, Staller K, Barshop K, Dai E, Newman J, Yoon S, et al. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J Gastroenterol. 2015;21:8103-8109. Available from: https://doi.org/10.3748/wjg.v21.i26.8103
Huang D, Liang L, Fang X, et al. The impact of psychological factors on the quality of life of patients with diarrhea predominant irritable bowel syndrome. Chin J Gastroenterol. 2015;35(09):599-605.
Schmulson MJ, Drossman DA. What is new in Rome IV? J Neurogastroenterol Motil. 2017;23(2):151-163. Available from: https://doi.org/10.5056/jnm16214
Zhang S, Wei W, Yang J. Consensus opinion on traditional Chinese medicine diagnosis and treatment of irritable bowel syndrome (2017). J Tradit Chin Med. 2017;58(18):1614-1620.
Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395-402. Available from: https://doi.org/10.1046/j.1365-2036.1997.142318000.x
Hubei Association of Traditional Chinese Medicine, Acupuncture and Moxibustion Association of Hubei Province. Operation specification for yin yang regulating moxibustion technology. J Hubei Univ Tradit Chin Med. 2022;24(05):92-94.
Gwee KA, Gonlachanvit S, Ghoshal UC, Chua ASB, Miwa H, Wu J, et al. Second Asian consensus on irritable bowel syndrome. Neurogastroenterol Motil. 2019;25(3):343-362. Available from: https://doi.org/10.5056/jnm19041
Oświęcimska J, Szymlak A, Roczniak W, Girczys-Połedniok K, Kwiecień J. New insights into the pathogenesis and treatment of irritable bowel syndrome. Adv Med Sci. 2017;62(1):17-30. Available from: https://doi.org/10.1016/j.advms.2016.11.001
Camilleri M. Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms. J Physiol. 2014;592(14):2967-2980. Available from: https://doi.org/10.1113/jphysiol.2014.270892
Thursday E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823-1836. Available from: https://doi.org/10.1042/bcj20160510
Menees S, Chey W. The gut microbiome and irritable bowel syndrome. F1000Res. 2018;7. Available from: https://doi.org/10.12688/f1000research.14592.1
Rea K, O’Mahony SM, Dinan TG, Cryan JF. The role of the gastrointestinal microbiota in visceral pain. Handb Exp Pharmacol. 2017;239:269-287. Available from: https://doi.org/10.1007/164_2016_115
Fukui H. Increased intestinal permeability and decreased barrier function: Does it influence the risk of inflammation? Inflamm Intest Dis. 2016;1(3):135-145. Available from: https://doi.org/10.1159/000447252
Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7(3):163-173. Available from: https://doi.org/10.1038/nrgastro.2010.4
Shi N, Li N, Duan X, Niu H. Interaction between the gut microbiome and mucosal immune system. Mil Med Res. 2017;4:14. Available from: https://doi.org/10.1186/s40779-017-0122-9
Donnachie E, Schneider A, Mehring M, Enck P. Incidence of irritable bowel syndrome and chronic fatigue following GI infection: a population-level study using routinely collected claims data. Gut. 2018;67(6):1078-1086. Available from: https://doi.org/10.1136/gutjnl-2017-313713
Moser G, Fournier C, Peter J. Intestinal microbiome-gut-brain axis and irritable bowel syndrome. Wien Med Wochenschr. 2018;168(3-4):62-66. Available from: https://doi.org/10.1007/s10354-017-0592-0
Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161:264–276. Available from: https://doi.org/10.1016/j.cell.2015.02.047
Swami T, Weber HC. Updates on the biology of serotonin and tryptophan hydroxylase. Curr Opin Endocrinol Diabetes Obes. 2018;25:12-21. Available from: https://doi.org/10.1097/med.0000000000000383
Martin CR, Osadchiy V, Kalani A, Mayer EA. The brain-gut-microbiome axis. Cell Mol Gastroenterol Hepatol. 2018;6:133-148. Available from: https://doi.org/10.1016/j.jcmgh.2018.04.003
Cheung SG, Goldenthal AR, Uhlemann AC, Mann JJ, Miller JM, Sublette ME. Systematic review of gut microbiota and major depression. Front Psychiatry. 2019;10:34. Available from: https://doi.org/10.3389/fpsyt.2019.00034
Rong X, Shu Q. Research progress on the mechanism and treatment of irritable bowel syndrome based on the brain-gut microbiota axis. Microbiol Bull. 2023;50(09):4190-4205.
Yin X, Wang F, Tian Y. The correlation between dysbiosis of gut microbiota and dysregulation of brain-gut axis in irritable bowel syndrome. Gastroenterology. 2017;22(01):59-62.
Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. Am J Gastroenterol. 2016;111(12):1824-1832. Available from: https://doi.org/10.1038/ajg.2016.434
Wu J, Lv L, Wang C. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Front Cell Infect Microbiol. 2022;12:827395. Available from: https://doi.org/10.3389/fcimb.2022.827395
Margolis KG, Cryan JF, Mayer EA. The microbiota-gut-brain axis: from motility to mood. Gastroenterology. 2021;160(5):1486-1501. Available from: https://doi.org/10.1053/j.gastro.2020.10.066
Bennett G, Talley NJ. Irritable bowel syndrome in the elderly. Best Pract Res Clin Gastroenterol. 2002;16(1):63-76. Available from: https://doi.org/10.1053/bega.2001.0266
Cai L, Huang S, Peng Z. Clinical efficacy of Anchang Tang in treating diarrhea predominant irritable bowel syndrome with liver depression and spleen deficiency syndrome, and its effects on intestinal barrier function, inflammatory factors, and neuropeptide Y levels. Chin J Gen Pract. 2020;23(09):1169-1174. Available from: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2019.00.569
Zhou Z, Jin S, Li M. Traditional Chinese Medicine Internal Medicine. Beijing: China Traditional Chinese Medicine Press; 2007. p. 235-236.
Xue R, Yang W, Liu D. Exploring the pathogenesis of diarrhea predominant irritable bowel syndrome based on the "brain-gut axis" and the thinking of acupuncture point selection. Clin J Acupunct Moxibustion. 2023;39(09):5-9.
Zhou Y, Chen M, Yang Y. Research progress on gut microbiota regulation of diarrhea-predominant irritable bowel syndrome based on the brain-gut axis. Chin J Tradit Chin Med. 2022;37(03):1582-1586.
Li M. Clinical and experimental study on microwave ginger separated moxibustion for the treatment of diarrhea predominant irritable bowel syndrome [D]. Nanjing: Nanjing Univ Tradit Chin Med; 2014.
Wang Y. Experimental study on the treatment of ulcerative colitis with liver depression and spleen deficiency by ginger separated moxibustion [dissertation]. Beijing: Beijing Univ Tradit Chin Med; 2008.
Zhou C, Wu L, Wu B. The effects of moxibustion and its products on visceral pain and colonic fluid metabolism in diarrhea-induced irritable bowel syndrome model rats. World Sci Technol Mod Tradit Chin Med. 2014;16(06):1261-1267.